Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc (TSX: CRDL )

2.610 +0.110 (+4.40%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cardiol Therapeutics Inc

Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
Exposures Product Safety
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients 
Via News Direct
Exposures Product Safety
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce... 
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics 
Via News Direct
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile
Exposures Product Safety
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in... 
Via Benzinga
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac... 
Via Newsfile
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
Via AB Newswire
Topics Stocks
Exposures US Equities
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center,... 
Via Newsfile
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
Air Pollution is a Global Heart and Lung Health Concern
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by... 
Via FinancialNewsMedia
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
The Healthcare Companies Fighting the World’s Biggest Killers
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the... 
Via FinancialNewsMedia
Tackling Recurring Health Conditions Offers Hope to Patients
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly... 
Via FinancialNewsMedia
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
Breakthroughs In Treating Killer Diseases Could Lengthen Life
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Market Movers. Today’s Top Stock Picks For New & Trending Opportunities
Market Movers. Today's Top Stock Picks For New & Trending Opportunities 
From Stockhouse Publishing
Via AccessWire
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
Exposures Product Safety
Heart Failure Treatment Offers Hope to Diabetics
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart... 
Via FinancialNewsMedia
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or... 
Via Newsfile
Exposures COVID-19
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the... 
Via Newsfile
Exposures COVID-19
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Oakville, Ontario--(Newsfile Corp. - April 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the... 
Via Newsfile
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.